 DURHAM, N.C., May 20, 2021 GLOBE NEWSWIRE -- Heat Biologics, Inc. Nasdaq: HTBX, a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced that the latest data from HS-110, the Companys lead product, has been accepted for poster presentation at the 2021 American Society of Clinical Oncology ASCO Annual Meeting, to be held virtually from June 4-8, 2021. The ASCO Annual Meeting is the largest international conference to showcase the latest advancements in oncology. 